Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Smith & Nephew plc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.48 (market cap $3.62B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 3.1× iShares MSCI United Kingdom (FTSE)'s market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Smith & Nephew plc for 121 Days on average.
| EWU | SNN | |
|---|---|---|
Market Cap | $3.62B | $11.10B |
Volume | 923,896 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $37.17 |
52-Week Low | $41.34 | $26.42 |
Typical Hold Time | 46 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU is trading at $46.52, up 1.28% today, but faces significant technical headwinds with a bearish overall signal. The stock shows mixed technical indicators with oversold RSI levels but strong bearish momentum signals from ADX. Recent UK market volatility, driven by rising gilt yields and inflation concerns, creates a challenging environment for this UK-focused ETF.
The outlook remains cautious as UK economic pressures mount, with rising borrowing costs and energy price inflation creating headwinds. Investment opportunity exists for contrarian investors given oversold technical conditions, but risks include continued UK market volatility and persistent inflation pressures that could pressure UK equities.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
